Drugs / Interferon-alpha
Interferon-alpha
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00329368 | Sep 2005 → Dec 2007 | cancer | Endocyte | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03638375 | Jul 2018 → Nov 2025 | drug allergy, poisoning | Leiden University | Unknown | No outcome recorded |
| Phase 215 trials · 3 missed | ||||||
| Phase 2 | NCT02838342 | May 2015 → Apr 2020 | neuroendocrine neoplasm | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2 | NCT01146535 | Jan 2011 → Dec 2012 | influenza | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00695019 | Jun 2009 → Nov 2011 | chronic hepatitis C virus infection | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Completed | Missed primary |
| Phase 2 | NCT00895947 | Apr 2009 → Jan 2010 | respiratory tract infectious disorder | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Completed | Missed primary |
| Phase 2 | NCT00690885 | Jun 2008 → Apr 2012 | chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00454181 | Feb 2007 → Sep 2009 | HIV infectious disease, papillomatosis | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Completed | Missed primary |
| Phase 2 | NCT00591188 | Dec 2006 → May 2008 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 2 | NCT00445523 | May 2006 → Jan 2008 | renal cell carcinoma | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00062010 | May 2004 → May 2011 | small cell lung carcinoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00580372 | Aug 2002 → Oct 2015 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT00911443 | Jul 2002 → Sep 2007 | melanoma | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01442779 | Sep 2000 → May 2007 | idiopathic pulmonary fibrosis | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 2 | NCT00504140 | Nov 1996 → Nov 2007 | osteosarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00038376 | May 1990 → Jun 2005 | mycosis fungoides | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00005665 | — | type 1 diabetes mellitus | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00330707 | Oct 1995 → Jun 2005 | superficial urinary bladder carcinoma | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00333840 | Jun 2000 → Mar 2012 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01060501 | Jul 1992 → Jul 2009 | rectal cancer | University of Ulm | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00581425 | Dec 2007 → Sep 2011 | basal cell carcinoma | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03121079 | May 2017 → Dec 2019 | interferon antiviral depressor | Peking University People's Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT00485563 Background | Jun 2007 → Aug 2008 | renal cell carcinoma | Endocyte | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00092222 Comparator | Oct 2004 → Oct 2026 expected | HIV infectious disease, cancer, human herpesvirus 8 infection, lymphoproliferative syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04116502 Comparator | Oct 2019 → Oct 2028 expected | acquired polycythemia vera | University of Birmingham | Recruiting | No outcome recorded |
| Phase 3 | NCT01681446 Comparator | Aug 2012 → Aug 2019 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT00311467 Comparator | Mar 2004 → May 2007 | renal cell carcinoma | Central European Cooperative Oncology Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00209209 Comparator | Jan 2004 → Dec 2018 | mantle cell lymphoma | European Mantle Cell Lymphoma Network | Unknown | Missed primary |
| Phase 3 | NCT00633542 Comparator | Jun 2003 → Sep 2007 | plasma cell myeloma | Marche Polytechnic University | Completed | No outcome recorded |
| — | NCT00838968 Comparator | Jan 2008 → Oct 2012 | hepatocellular carcinoma | Fudan University | Withdrawn | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon Alpha | “A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha...” NCT00911443 ↗31“Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.” NCT00311467 ↗ “Maintenance with interferon alpha will be administered until disease progression.” NCT00580372 ↗ “using interferon-alpha (Roferon) and Isotretinoin (Accutane).” NCT00038376 ↗ |
| Known as | aIFN | “A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha...” NCT00911443 ↗ |
| Known as | alpha-interferon | “Alpha-interferon will be given once a day for an initial period of 12 weeks.” NCT00038376 ↗ |
| Known as | hrIFN-a | “We hypothesize that ingested human recombinant interferon-alpha (hrIFN-a) will prolong the "honeymoon" period and enhance B cell survival in type 1 diabetes in a phase II...” NCT00005665 ↗ |
| Known as | IFN-a | “interferon-alpha (IFN-a) subcutaneous (SC) injections” NCT00333840 ↗ |
| Known as | IFN-alpha | “interferon-alpha (IFN-alpha)” NCT01681446 ↗ |
| Known as | IFN-α | “postresection intravesical BCG (81 mg [n=50] or 27 mg [n=19]) or BCG (27 mg) with interferon alpha (IFN-α; n=30).” PMID 21163569 ↗ Dec 2010 |
| Known as | INF-a | “interferon-alpha (INF-a)” NCT00333840 ↗ |
| Known as | INF-alpha | “the cytokines Interleukin-2 (IL-2) and Interferon-alpha (INF-alpha)” NCT00485563 ↗ |
| Known as | Roferon | “using interferon-alpha (Roferon) and Isotretinoin (Accutane).” NCT00038376 ↗ |
| Modality | Protein / enzyme biologic | “human recombinant interferon-alpha” NCT00005665 ↗ |
| Route | Oral | “ingested (oral)” NCT00005665 ↗ |